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Abstract
Background: Cancer-associated pain is a major cause of poor quality of life in cancer patients and is frequently
resistant to conventional therapy. Recent studies indicate that some hematopoietic growth factors, namely
granulocyte macrophage colony stimulating factor (GMCSF) and granulocyte colony stimulating factor (GCSF), are
abundantly released in the tumor microenvironment and play a key role in regulating tumor-nerve interactions and
tumor-associated pain by activating receptors on dorsal root ganglion (DRG) neurons. Moreover, these
hematopoietic factors have been highly implicated in postsurgical pain, inflammatory pain and osteoarthritic pain.
However, the molecular mechanisms via which G-/GMCSF bring about nociceptive sensitization and elicit pain are
not known.
Results: In order to elucidate G-/GMCSF mediated transcriptional changes in the sensory neurons, we performed a
comprehensive, genome-wide analysis of changes in the transcriptome of DRG neurons brought about by
exposure to GMCSF or GCSF. We present complete information on regulated genes and validated profiling analyses
and report novel regulatory networks and interaction maps revealed by detailed bioinformatics analyses. Amongst
these, we validate calpain 2, matrix metalloproteinase 9 (MMP9) and a RhoGTPase Rac1 as well as Tumor necrosis
factor alpha (TNFα) as transcriptional targets of G-/GMCSF and demonstrate the importance of MMP9 and Rac1 in
GMCSF-induced nociceptor sensitization.
Conclusion: With integrative approach of bioinformatics, in vivo pharmacology and behavioral analyses, our results
not only indicate that transcriptional control by G-/GMCSF signaling regulates a variety of established pain
modulators, but also uncover a large number of novel targets, paving the way for translational analyses in the
context of pain disorders.
Background
Pain is one of the most severe and common symptoms
of a variety of cancers and is a primary determinant of
the poor quality of life in cancer patients. In a large
number of clinical cases, cancer-associated pain, particu-
larly the neuropathic component thereof, is resistant to
conventional therapeutics or their application is severely
limited owing to the widespread side effects. Because
many types of carcinomas and sarcomas metastasize to
skeletal bones, they are associated with spontaneous
pain, hyperalgesia and allodynia. As potential mecha-
nisms, tumor-derived factors, such as NGF [1], endothe-
lins [2-4], amongst others, have been studied, which
either directly activate nociceptive nerves or sensitize
them towards sensory stimuli [5,6].
Several types of non-hematopoietic tumors secrete
hematopoietic colony stimulating factors, which act on
myeloid cells and tumor cells [7]. In a recent study, we
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demonstrated that receptors and signaling mediators of
granulocyte- and granulocyte-macrophage colony stimu-
lating factors (G-/GMCSF) are also broadly expressed
on sensory nerves in mouse models of bone metastases
as well as in human biopsies of pancreatic adenocarcin-
oma [8]. Using animal models of bone metastases which
closely mimic the nature and progression of cancer pain
in humans, we reported that GCSF and GMCSF directly
act on receptors on diverse DRG neurons to subserve
important functions in the generation of pain hypersen-
sitivity in tumor-affected regions [8]. Importantly, behav-
ioral, electrophysiological and biochemical experiments
demonstrated sensitization of sensory nerves towards
thermal and mechanical stimuli as well as an increase in
neurotransmitter release upon exposure to G-/GMCSF.
By adapting RNAi methodology in vivo, we demon-
strated that a specific loss of GMCSFRα in DRG led to a
reduction in bone tumor–evoked pain without inter-
fering with the tumor growth, indicating that GMCSF
signaling in peripheral nerves contributes substantially
to cancer pain [8]. Recent studies on post-surgical pain
and inflammatory pain also point to a key role for these
cytokines [9-12].
G-/GMCSF activates the JAK family of receptor
tyrosine kinases, which unfolds its activity by not only
regulating enzymes and target proteins within its local
milieu, but importantly also by activating the STAT fam-
ily of transcription factors, which subsequently dimerize
and translocate to the cell nucleus to regulate gene
expression [13]. Albeit we have reported local, acute
activation of the ERK Kinase as well as PI3 Kinase in sen-
sory nerves upon a short-term exposure to G-/GMCSF,
nothing is known so far about the nature of genes regu-
lated transcriptionally in DRG neurons upon exposure to
G/GMCSF. However, long-term transcriptional mecha-
nisms of G/GMCSF action are arguably of even greater
importance in pathophysiological states involving chronic,
continual release of G/GMCSF, such as tumor-affected
tissues, rheumatoid arthritis, amongst others [14,15].
Addressing precise mechanisms via which the G-/
GMCSF-JAK-STAT pathway elicits long-term nociceptive
sensitization is thus important for understanding mecha-
nisms of cancer pain and other chronic disorders asso-
ciated with G-/GMCSF release.
In lieu of the attractive therapeutic opportunities
offered by these findings, we aimed to elucidate cellular
targets of G/GMCSFR in DRG neurons, particularly with
respect to transcriptional regulation. Not only did we
find a variety of known, established ‘pain-related’ media-
tors to be transcriptional targets of G-/GMCSF, but also
several protein-protein interaction hubs were observed
to be under G-/GMCSF regulation in sensory neurons
via detailed bioinformatics analyses. Behavioral and
pharmacological analyses on 4 of the emerging targets
confirmed that Rac1 and Matrix metallopeptidase 9
(MMP9) contribute to GMCSF-induced nociceptive
sensitization. These integrative approaches advance our
understanding of chronic pain mechanisms and hold
promise in the development of novel therapeutic
approaches.
Materials and methods
Animal usage
All animal usage procedures were in accordance with
ethical guidelines laid down by the International Associ-
ation of the Study of Pain and the local governing body
(Regierungspräsidium Karlsruhe). All behavioral measure-
ments were done in awake, unrestrained, age-matched
adult (more than 2 months-old) C57/Bl6 mice. Mice were
housed in plastic cages, with ambient temperature and a
12 h diurnal light cycle. Food and water were provided
ad libitum.
Sensory neuronal cultures and G-/GMCSF treatment
Adult DRG neuronal cultures were prepared following
the protocol explained previously [8]. Briefly, neuronal
cells isolated from adult wild type mice were seeded on
Poly-L-Lysine coated cover slips and maintained in F12
Media (Sigma) supplemented with 15% Amino Acids
(Gibco), 10% bovine serum (Invitrogen), 1% Penicillin/
Streptomycin (Gibco), 0.5% L-Glutamine (Gibco) and
Nerve Growth Factor (100 mg ml-1, Roche). 4 days old
enriched adult neuronal cultures were starved of growth
factors and serum for 4 h. At the end of 4 h, starving
culture medium was replaced with medium containing
0.5% Fetal bovine serum (Life Technologies, 10270106)
together with either 1× PBS (vehicle) or 200 ng/mL of
murine GMCSF (Peprotech, 315–03) or 200 ng/mL of
murine GCSF (Peprotech 250–05) dissolved in 1×PBS.
Neurons were left in the incubator for 24 h. Each treat-
ment was performed in triplicate culture wells (n = 3) to
test biological variability. At the end of 24 h, total RNA
was isolated and used for microarray expression or qRT-
PCR analysis.
RNA isolation from cultured sensory neurons and DRGs
Total RNA from cultured sensory neurons treated with
murine GMCSF or GCSF or PBS for 24 h was isolated
using mirVana™ miRNA Isolation Kit (Ambion, AM 1561)
following manufacturer’s instructions and dissolved in
20 μl of nuclease-free water. Purification steps were per-
formed using RNAse-free DNAse kit (Qiagen, 79254)
following manufacturer’s instructions. RNA concentration
was determined using the NanoDrop spectrophotometer
(NanoDrop Technologies, Wilmington, Germany) and the
quality of total RNA was checked by gel analysis using the
total RNA Nanochip assay on an Agilent 2100 Bioanalyzer
(Agilent Technologies GmbH, Waldbronn, Germany).
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Only samples with RNA index values greater than 7 were
selected for mRNA profiling. 200 ng of total RNA from
each biological sample was used as starting material for
mRNA expression analysis.
For in vivo testing, lumbar DRGs L3, L4 and L5 were
collected at 25 h, 36 and 48 h after bilateral intraplantar
application of 20 ng murine GMCSF and flash frozen in
liquid nitrogen. Total RNA was isolated and processed
following the same protocol explained above for cultured
sensory neurons.
Microarray expression, networking and gene ontology
analysis
The mRNA profiling was performed on polyadenylated
RNA using Illumina mouse sentrix-6 chips. cDNA
library preparation, hybridization and scanning steps
were performed by employing in-house standardized
protocols and including stringent positive and negative
controls at each step at the genomics and proteomics
core facility, German Cancer Research Centre (DKFZ,
Heidelberg, Germany). The array intensity data were
imported into Beadstudio ver. 3 from Illumina and the
quantile array normalization method was employed to
account for intra- and inter-array variations in expres-
sion intensities within each experimental group [16].
Magnitude of induction or repression of individual tran-
script was compared over vehicle-treated samples. To be
able to understand the magnitude of regulation at
transcript level, we first converted probe-level signals to
transcript-level signals by using in house developed Perl
scripts and applying following criteria – i) Take the aver-
age fold-change if all the probes for one transcript
showed the same direction (positive or negative) of regu-
lation, ii) Discard the transcripts for which different
probes showed different directions of regulation iii) Take
the regulation value from the majority of probes if only
one probe out of several probes is showing different
expression signals.
All the networking analyses of the expression data
were performed using MetaCore™ software in which a
network is built around an initial list of “seed nodes,”
which can originate from the uploaded experiment, or
be manually assembled, or else be automatically conver-
ted by MetaCore™ from a list of genes. For the gene
ontology enrichment analyses, we used software called
bioCompendium (http://biocompendium.embl.de) deve-
loped at the European Molecular Biology Laboratory,
Heidelberg, Germany.
GMCSF and inhibitors application in vivo
Murine GMCSF was purchased from Peprotech, dissol-
ved in 1× PBS of physiological PH and 20 ng was
applied into the intraplantar surface of adult C57/Bl6
mice unilaterally for 4 times at 8 h intervals. Inhibitors for
MMP-9 (CAS 1177749-58-4) and Rac1 (1090893-12-1)
were purchased from Calbiochem and dissolved in 10%
and 50% Dimethyl Sulfoxide (DMSO, Applichem), res-
pectively. Calpain 1/2 inhibitor (Calpain inhibitor III,
A3672, 0250) was purchased from Sigma-Aldrich and
dissolved in 20% DMSO. TNFα inhibitor was purchased
from Pfizer (Enbrel®)) and diluted in 1× PBS. One hour
after the last GMCSF dosage application, different groups
of mice received 0.15 pmoles, 1.5 nmoles, 10 nmoles or
100 pmoles of MMP-9 or Rac1 or Calpain 1/2 or TNFα
inhibitors, respectively, in 10 μl volume of vehicle into the
same paw into which multiple dosages of GMCSF were
applied. BSA dissolved in 1× PBS was used as vehicle
control for TNFα inhibition experiments. Mechanical
hyperalgesia was recorded after 4 and 8 h after the last
GMCSF dosage application while thermal hypersensitivity
was recorded after 5 and 9 h of the last GMCSF dosage
application.
Mechanical and thermal pain behavioral tests
Mice were habituated to the experimental setup in at
least 2 separate sessions within the week preceding the
time of behavioral testing. The observer was fully
blinded to the identity of the groups in all behavioral
tests. To measure mechanical sensitivity, animals were
placed on an elevated wire grid and the plantar hind
paw was stimulated using calibrated von Frey monofila-
ments of 0.07 g, 0.16 g, 0.4 g and 1.0 g strength (Bioseb,
France). Paw withdrawal was recorded as a positive
response. Data is expressed as percentage of frequency
of response over 5 stimulations and data from represen-
tative filament is shown in this manuscript. For thermal
nociceptive testing, radiant heat was applied using
Hargreaves’ apparatus (Ugo Basile, Italy) to the plantar
surface of the hind paw, until mice retract it sharply.
The time taken to retract (paw withdrawal latency) the
hind paw was recorded. A cut-off of 15 seconds heat
exposure was followed in order to avoid any potential
damage to the tissue.
Quantification of mRNA expression
We used NanoString-nCounter™ based gene quantifi-
cation method to validate microarray expression data.
Probes specifically targeting the desired gene of inter-
est were obtained from Nanostring Technologies,
USA and analyses were performed at the nCounter
core facility of the Medical Faculty of Heidelberg,
Heidelberg University, Germany. Two hundred ng of
total RNA were used to analyze the expression of
diverse target genes, using 5 housekeeping genes, namely
Clathrin, heavy polypeptide (Cltc), Glyceraldehyde-3-
phosphate dehydrogenase (Gapdh), glucuronidase beta
(Gusb), Hypoxanthine guanine phosphoribosyl transferase
(Hprt) and Tubulin, beta 5 class I (Tubb5), as internal
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controls. Expression of target genes was analyzed by
comparing treated and control samples. Fold-change of
test gene was expressed as arithmetic average value over
all 5 housekeeping genes.
Taqman assays (Life Technologies, USA) were used
for QRTPCR-based quantification of Rac1 (assay ID
Mm01201653_mH), Calpain2 (assay ID Mm00486669_m1),
MMP9 (assay ID Mm00600164_g1) and TNFα (assay ID
Mm00443260_g1). 20 ng of total RNA was used to prepare
the cDNA using random primers from the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
4368814) following manufacturer’s instructions. Four μl of
prepared cDNA were PCR amplified in each reaction
using mRNA-specific primers and TaqMan® Universal
Master Mix II, (Applied Biosystems, 4440040) following
manufacturer’s instructions on Chromo 4 detection sys-
tem (BioRad, USA). The expression level of the target
mRNA was normalized to the expression of Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH, assay ID
4352932E, Applied biosystems). Each mRNA was ampli-
fied from triplicate samples and Ct values were recorded.
Fold-change in the mRNA expression in vehicle- or
GMCSF-treated sensory neuronal cultures was calculated
using DDCT method [17] which measures the relative
change in expression of a mRNA from treatment to
control compared to the reference gene.
Data analysis
All data are presented as mean ± standard error of the
mean (S.E.M.), Two-tailed Student’s t-test or the Ana-
lysis of Variance (ANOVA) for repeated measures
followed by post-hoc Fisher’s LSD test was utilized to
determine statistically significant differences (p < 0.05),
unless mentioned otherwise for a particular experiment.
Results
GMCSF-mediated changes in the gene expression
repertoire in sensory neurons
To investigate transcriptional expression changes caused
by exposure to GMCSF or GCSF application at a
genome-wide level, we performed a genome-wide gene
profiling screen from cultured DRG neurons derived
from adult mice. Neuron-enriched cultures were starved
of growth factors and serum for 4 h and treated with
GMCSF or GCSF (200 ng/mL in PBS) or vehicle (PBS)
in medium containing 0.5% serum for 24 h. Total RNA
isolated from 3 such independent experiments was
subjected to quality control as described under methods
and processed in profiling experiments using Illumina
prespotted arrays. cDNA library preparation, hybridi-
zation and scanning steps were performed by employing
in-house standardized protocols, and including stringent
positive and negative controls at each step. The array
intensity data were imported into Beadstudio ver. 3 from
Illumina and the quantile array normalization method
was employed to correct for systematic differences
between arrays which do not represent a biological
variation of interest between experimental groups [18].
Magnitude of fold-induction or fold-repression of indi-
vidual transcript was compared over vehicle-treated
samples, as described in our previous studies [19].
Data acquired from the array provided expression sig-
nals from 46090 probes targeting 30723 genome-wide
transcripts. Out of 30723 transcripts arrayed 15833 and
16882 showed significant fold change in their expression
in GMCSF-treated and GCSF-treated samples, respect-
ively, as compared to vehicle-treated samples (P ≤ 0.05,
two-tailed t-test assuming equal variance, Benjamini and
Hochberg false discovery rate correction, n = 3 inde-
pendent profiling experiments) (Figure 1 and Additional
file 1: Table S1). Because both GMCSF and GCSF act in
a pronociceptive manner, we then studied commonly
regulated transcripts and found that 3898 transcripts
showed significant upregulation with GMCSF as well as
with GCSF as stimuli for DRG neurons (Figure 1B).
These included several genes which have been im-
plicated in nociceptive modulation, such as chemokine
(C-C motif ) ligand 2 and 3 (Ccl2 and Ccl3) [20,21],
transient receptor potential cation channel, subfamily V,
member 1 (TRPV1), a molecular sensor and transducer
for heat, protons and algogens [22], amongst others (a
few examples are shown in Figure 1C). Moreover, 9254
transcripts were commonly downregulated upon expo-
sure with GMCSF as well as with GCSF. These also
included several pain-related known genes, such as the
voltage-dependent calcium channel subunit aplha2/
delta1 (Cacna2d1) [23], the AMPA receptor interacting
protein, GRIP1 [24,25], amongst others (Figure 1C). Inter-
estingly, however, 421 genes showed reciprocal regulation
upon exposure to GMCSF or GCSF (Figure 1B), e.g. the
nociceptive modulatory chemokine (C-C motif) ligand
(Ccl5) [26] and the matrix metalloprotease 3 (MMP3)
[27,28] were significantly upregulated after GMCSF
exposure, but downregulated upon exposure to GCSF
(Figure 1C). In general, genes encoding nociceptive modu-
lating pronociceptive chemokines and cytokines appeared
more strongly regulated by GMCSF signaling than by
GCSF signaling in DRG neurons (some examples in
Figure 1C).
To test the validity of the microarray data reported
above, we performed quantitative measurements of the
expression of several candidate regulated genes using
Nanostring-nCounter technique. Amongst putatively
regulated transcripts in the GMCSF-mediated gene pool,
we tested 100 genes quantitatively and found that 78
genes were regulated as predicted by profiling data,
which included up-regulated genes such as chemokine
(C-C motif ) ligand 5 (Ccl5), interleukin 1 alpha (Il1a),
Bali et al. Molecular Pain 2013, 9:48 Page 4 of 16
http://www.molecularpain.com/content/9/1/48
Ccl3 (Figure 2A) and down-regulated genes such as
Cacna2d1, synapsin II (Syn2), amongst others (Figure 2B).
Along the same lines, GCSF-mediated regulation of
several genes, including pain-related genes such as
calcitonin/calcitonin-related polypeptide, alpha, transcript
variant 1(Calca), Ccl3, and fibroblast growth factor 7
(Fgf7) amongst several others could be confirmed using
the same PCR-based methodology (Figure 2C, 2D).
These results thus validate the results obtained with
the microarray expression arrays via an independent
method.
In a next step, to understand systems level interactions
in the GMCSF- or GCSF-mediated gene pools, we perfor-
med a direct-interactions analysis using Metacore software
[19,29]. When we applied this to all significantly regulated
transcripts following the criteria explained above for
Figure 1, it yielded too dense a network to allow mea-
ningful interpretations (data not shown). Therefore, we
stringently filtered out the transcripts which showed at
least 4-fold up- or down-regulation upon exposure to
GMCSF (thus arriving at 661 transcripts) or GCSF (611
transcripts). Of these, only 467 GMCSF-target genes and
Figure 1 GMCSF- or GCSF- mediated gene pool in the peripheral sensory neurons. (A) Heat map representation of significantly-regulated
transcripts showing more than two-fold change (two-tailed t-test assuming equal variance, P with Benjamini and Hochberg False Discovery Rate
correction <0.05) following chronic exposure to GMCSF or GCSF in sensory neurons of the DRG. The color scale represents quantile normalized
hybridization intensities for each gene. (B) Venn diagram representing the number of genes commonly or differentially regulated by GMCSF
and GCSF exposure in DRG neurons. (C) Selected pain-related genes that were significantly regulated (two-tailed t-test assuming equal variance,
P with Benjamini and Hochberg False Discovery Rate correction <0.05). Genes commonly (green text) or differently (red text) regulated by GMCSF
and GCSF stimulation in sensory neurons are shown. Gene regulation confirmed by qRT-PCR analysis is highlighted in bold text.
Bali et al. Molecular Pain 2013, 9:48 Page 5 of 16
http://www.molecularpain.com/content/9/1/48
454 GCSF-target genes were well annotated with known
higher level mapping in Metacore and were used for the
direct-network analysis. The network map generated by
the genego direct-interaction network analysis tool re-
vealed a dense network of genes in the GMCSF-target
pool with 3 major nodal points namely, two transcription
factors, E26 avian leukemia oncogene 1, 5' domain, tran-
script variant 2 (Ets1), Hypoxia inducible factor 1 alpha
subunit (Hif1a) and a metallo-protease, namely Mmp9
(Figure 3). These 3 nodal points are intensively related to
many kinases such as mitogen-activated protein kinase 3
(MAPK3), generic binding proteins such as Synapsin, Ras
super family members such as Rac1, receptors like Toll-
like receptor 2 encoding gene (Tlr2), all of which are
either directly or indirectly implicated in nociceptive
mechanisms. Similarly, the direct-interaction network for
the GCSF-mediated gene pool also revealed a densely
connected network with genes encoding the key post-
translational sumoylation protein (Sumo1), the cyclin-
dependent kinase inhibitor 1A (Cdkn1a), CREB binding
protein (Crebbp or CBP), calpain 2 (Capn2), MAPK3 and
the RhoGTPase Rac1 (Rac1) serving as major nodal
points. These nodes are intensively linked to genes
encoding Calmodulin 2 (Calm2), the Transient Receptor
Family channel V1 (Trpv1 or capsaicin receptor), Actin-
modulatory protein profilin 1 (Pfn1), among several others
(Figure 4). These results indicate that GMCSF- and
GCSF-signaling interlinks transcriptional and post-trans-
lational modification mechanisms to key nociceptive
modulatory proteins. We further performed direct inter-
action network analysis on genes that were commonly
regulated following GMCSF or GCSF exposure. These
commonly-regulated networks revealed shared nodal
points such as Rac1, mitogen-activated protein kinase 3
(Mapk3), among others (Additional file 2: Figure S1 and
Additional file 3: Figure S2).
A gene ontology enrichment analysis on the same
subsets of GMCSF- or GCSF-target genes performed
using the bioCompendium software revealed that a
major proportion of transcripts (> 50%) show protein-
binding activity. Interestingly, cytokine activity and
chemokine-receptor binding categories were found to be
represented in the molecular function enrichment ana-
lysis on GMCSF-target pool in DRG neurons (Additional
file 4: Figure S3), consistent with our observation of high
regulation levels of several nociception-related cytokines
and chemokines.
In the next step, by using the same subsets of sig-
nificantly regulated GMCSF- or GCSF-modulated genes
as explained for Figure 1A, we performed a network
analysis in which networks are built on the basis of rela-
tionships and interactions contained in the MetaCore™
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Figure 2 Nanostring-nCounter-based validation of selected genes those are up-regulated by GMCSF (A), down-regulated by GMCSF
(B), up-regulated by GCSF (C) and down-regulated by GCSF (D) in the sensory neurons. Fold-change expression in the genes is expressed
as arithmetic average over 5 housekeeping genes namely Cltc, Gapdh, Gusb, Hprt and Tubb5 in all panels. * P < 0.05, one-way ANOVA followed by
Fisher’s LSD Post-hoc analysis.
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Database. Interestingly, the network which emerged with
a top rank from the gene pool of GMCSF-targets in
sensory neurons revealed that the classical signaling
cascade consisting of JAK kinases (JAK1 and JAK2) and
STAT transcription factors, STAT1 and STAT3 are tightly
linked to Tumor necrosis factor-alpha (TNF-alpha) and
its receptor TNF-R1, both of which were observed to be
directly regulated by GMCSF in sensory neurons in our
profiling analyses (Additional file 5: Figure S4). Moreover,
a link to NF-kappa-I Kappa B signaling, which has also
Figure 4 Direct-interactions-network analysis on GCSF-mediated gene pool with fold change between +4 and −4 and as compared to
control-treated sensory neurons and P-BH < 0.05 (t-test, P with Benjamini and Hochberg False Discovery Rate < 0.05). Genes upregulated
and downregulated in GCSF-dependent manner are marked with red and blue circles, respectively. Please see Additional file 3: Figure S2 for
information on legends.
Figure 3 Direct-interactions-network analysis on GMCSF-mediated gene pool with fold-change between +4 and −4 as compared to
control-treated sensory neurons and P-BH < 0.05 (t-test, P with Benjamini and Hochberg False Discovery Rate < 0.05). Genes upregulated
and downregulated in GMCSF-dependent manner are marked with red and blue circles, respectively. Please see Additional file 3: Figure S2 for
information on legends.
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been implicated in sensory neurons [30], was also appa-
rent (Additional file 5: Figure S4). These findings further
indicate a close link between GMCSF-induced transcrip-
tional control and induction of key nociceptive modula-
tors, such as TNF-alpha.
Functional significance of GM-/GCSF-regulated gene pool
in GM-/GCSF-induced nociceptive hypersensitivity
Finally, to functionally validate our results on GMCSF-
and GCSF-associated genes, we selected protein prod-
ucts of a set of four candidate genes from different
functional classes and with functional relevance to pain
modulation, namely the RhoGTPase Rac1, the matrix
metallopeptidase 9 (MMP9), a chemokine TNF-alpha
and a generic protease calpain 2. To confirm GMCSF-
mediated modulation of these four genes, we compared
their mRNA expression in the total RNA isolated from
the DRG neuronal cultures following chronic treatment
with GMCSF or vehicle, i.e. a similar paradigm as with
the expression array screening. Analysis of results con-
firmed GMCSF-mediated robust upregulation of Rac1,
MMP9, TNFα and Calpain 2 as compared to vehicle-
treated samples (Figure 5A, *P < 0.05, one-way ANOVA
followed by Fisher’s LSD Post-hoc analysis).
In previous studies, we have analyzed short-term
effects of acute exposure to GCSF and GMCSF [8].
However, in order to mimic chronic clinical conditions
which are associated with longer exposure to G-/
GMCSF and to match the course of the following beha-
vioral experiments with the time frame of our gene
regulation studies, we administered multiple dosages of
20 ng murine GMCSF as described in the scheme shown
in Figure 5C and inhibitors were applied one hour after
the last GMCSF dosage application. Mechanical sensitiv-
ity was recorded upon ipsilateral plantar application of
graded von Frey filaments at 3 h and 7 h post injection
and thermal sensitivity was recorded using Hargreaves’
apparatus at 4 and 8 h following inhibitor application.
For in vivo confirmation of GMCSF-mediated regulation
of Rac1, MMP9, Calpain2 and TNFα, DRGs were col-
lected at 24, 36 and 48 h after the first GMCSF dosage
application. QRTPCR-based expression analysis confir-
med GMCSF-mediated up-regulation of Rac1, MMP9,
Calpain 2 and TNFα in the DRGs of GMCSF-treated
mice as compared to the vehicle-treated group of mice
(Figure 5B, *P < 0.05, one-way ANOVA followed by Fisher’s
LSD Post-hoc analysis).
Peripheral Rac1 activation is required for GMCSF-
mediated mechanical and thermal hyperalgesia
In our profiling analysis and quantitative PCR analysis,
Rac1 expression increased significantly in DRG neurons
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Figure 5 QRTPCR-based validation of GM-CSF-induced regulation of the expression of Rac1, MMP9, Calpain2 and TNFα in vitro as well
as in vivo. Gene regulation at 24 h following the start of GMCSF exposure in cultured sensory neurons is shown in (A) and in DRGs at different
time points following intraplantar GMCSF injection is shown in (B). * denotes P≤ 0.05 as compared to vehicle group, One-Way ANOVA followed
by Fisher’s LSD Post-hoc analysis, n = 3 mice per group. (C) Schematic representation of the protocol followed to investigate changes in GMCSF-
mediated mechanical and thermal hypersensitivity upon inhibition of Rac1 or MMP9 or Calpain 2 or TNFα in vivo.
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following a 24 h-long exposure to GMCSF or GCSF. In
spinal neurons, regulation of Rac1 activity is known to
impact dendritic spine morphology and density as well
as pain hypersensitivity following spinal cord injury [31].
However, Rac1 has not been addressed in peripheral
sensory neurons in the context of nociceptive modu-
lation in sensory neurons. To address whether Rac1 is
upregulated at 24 h after exposure to GMCSF contrib-
utes to GMCSF-evoked nociceptive hypersensitivity, we
selected dosage of the Rac1-specific inhibitor, NSC23766
[32], based on the concentration used by Tan et. al [31]
in rats. Extrapolating this concentration to mice and to
account for the dilution factor in the CSF, we selected
approx. 10 times lesser concentration (1.5 nmoles) in
the current study. We divided mice treated with GMCSF
over 24 h into 2 groups – one received a single
intraplantar injection of NSC23766, a specific Rac1
inhibitor (1.5 nmoles in 10 μl of 50% DMSO) and the
other group received a single intraplantar injection of
vehicle (10 μl of 50% DMSO) 1 h after the last plantar
treatment with GMCSF; GMCSF-mediated mechanical
and thermal hypersensitivity was analyzed approx. 3 h
and 7 h after inhibitor or vehicle application in both
groups. Whereas mice injected with vehicle showed
significant mechanical hypersensitivity to 0.16 g of von
Frey force as compared to vehicle at 3 h as well as 7 h
after the inhibitor application (* P = 0.003 at 3 h and
0.007 at 7 h, One-Way ANOVA with repeated measures
followed by Fisher’s LSD Post-hoc analysis, n = 6 mice per
group), mice injected with the Rac1 inhibitor did not show
any significant deviation from basal response frequencies
to 0.16 g force (P > 0.05 as compared to basal; n = 6 mice; †
P < 0.01 between groups, One-Way ANOVA with repeated
measures followed by Fisher’s LSD Post-hoc analysis,
Figure 6A and Additional file 6: Table S2). Along the same
lines, vehicle-treated mice showed a significant decrease in
withdrawal response latencies to plantar heat (i.e. thermal
hyperalgesia) as compared to basal values (* P = 0.003 and
0.002 at 4 and 8 h post inhibitor application, respectively,
One-way ANOVA followed by Fisher’s LSD Post-hoc ana-
lysis, Figure 6B and Additional file 7: Table S3). In con-
trast, Rac1-inhibitor-treated mice did not show thermal
hyperalgesia at 4 h after inhibitor application; furthermore,
thermal hyperalgesia at both time points tested after
inhibitor treatment was significantly reduced as compared
to vehicle-treated mice († P = 0.033 at 4 h and P = 0.019 at
8 h between vehicle- and Rac1-inhibitor-treated mice,
One-way ANOVA with repeated measures followed by
Fisher’s LSD Post-hoc analysis, Figure 6B Additional file 7:
Table S3). As a control to rule out systemic effects of Rac1
inhibitor, we injected inhibitor or vehicle into the paw
contralateral to the paw injected with GMCSF – this treat-
ment failed to block GMCSF-induced mechanical and
thermal hyperalgesia in the paw ipsilateral to the GMCSF-
injected paw (Additional file 8: Figure S5 panels A and C,
*P < 0.05 following GMCSF administration, One-Way
ANOVA with repeated measures followed by Fisher’s LSD
Post-hoc analysis, n = 6 mice). In the same paradigm,
mechanical or thermal response frequencies were unal-
tered as compared to the basal readings in the paw con-
tralateral to the GMCSF-injected paw (Additional file 8:
Figure S5 panels B and G, P > 0.05). Similarly, injection of
the same dosage of Rac1 inhibitor unilaterally into the
intraplantar surface in the absence of GMCSF treat-
ment did not affect mechanical and thermal response
frequencies when tested up to 7 h post-injection
(Additional file 9: Figure S6, panels A and B). Thus,
these results indicate that locally activated Rac1 spe-
cifically contributes to both mechanical and thermal
hypersensitivity induced by a prolonged peripheral ex-
posure to GMCSF.
Peripheral MMP9 activation is required for ongoing
nociceptive sensitization
In the current study, expression of Mmp9, the gene
encoding the extracellular matrix protease MMP9,
increased by about 5-fold in DRG following GMCSF
stimulation, but not following GCSF stimulation. Given
that MMP9 has been shown to participate in inflamma-
tory as well as neuropathic pain in a peripheral as well
as a spinal context [33-35], we were interested in
addressing whether GMCSF-induced upregulation of
MMP9 was functionally linked to GMCSF-evoked exag-
geration of mechanical and thermal sensitivity. Using the
scheme shown in Figure 5C and described in detail
above for the Rac1-associated experiments, we adminis-
tered a single dose of 0.15 pmoles of a potent MMP9
inhibitor in 10 μl of 10% DMSO (vehicle) to the plantar
surface 1 h after the last plantar administration of
GMCSF. We selected the MMP9 inhibitor dosage based
on its high potency (IC50 = 5nM) and its reported intra-
thecal dosage to attenuate CFA-mediated mechanical
allodynia in rats [36]. Upon peripheral MMP9 inhibition,
we observed a complete abrogation of GMCSF-evoked
mechanical hypersensitivity to 0.16 g of von Frey force
as well as thermal hyperalgesia at 3–4 h after MMP9
inhibitor application (Figure 6C and Additional file 6:
Table S2 *P < 0.05 as compared to basal values; † P < 0.05
as compared between inhibitor and vehicle groups; One-
way ANOVA with repeated measures followed by Fisher’s
LSD Post-hoc analysis). This effect on mechanical and
thermal hyperalgesia was partially or fully lost, respect-
ively, at 7–8 h after inhibitor application, reflecting the
duration of action of a single dose of the MMP9-inhibitor
at the low dose utilized in this study (Figure 6D and
Additional file 7: Table S3). Similar to the experiments
described above with Rac1 inhibition, we observed that
injection of the MMP9 inhibitor in the paw contralateral
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to the paw injected with GMCSF did not significantly
influence GMCSF-mediated mechanical and thermal
hyperalgesia in the paw ipsilateral to the GMCSF-injected
paw (Additional file 8: Figure S5 panels B and D, *P < 0.05
following GM-CSF administration as compared to basal
values, One-way ANOVA with repeated measures fol-
lowed by Fisher’s LSD Post-hoc analysis) nor induced
hyperalgesia in the paw contralateral to the GMCSF-
injected paw (Additional file 8: Figure S5, panels F and H,
P > 0.05). Furthermore, injection of the MMP9 inhibitor in
the absence of GM-CSF did not affect nociceptive sensi-
tivity (Additional file 9: Figure S6 panels C and D, P > 0.05
as compared to basal values, One-way ANOVA with
repeated measures followed by Fisher’s LSD Post-hoc
analysis). These results indicate that similar to Rac1, peri-
pheral MMP9 activation is important for ongoing noci-
ceptive sensitization that develops upon a prolonged
exposure to GMCSF.
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Figure 6 In vivo validation of GM-CSF transcriptional targets in DRG neurons in the context of nociceptive sensitization evoked by
long-term exposure to GMCSF. Changes in GMCSF-mediated mechanical hypersensitivity upon inhibition of Rac1 (A), MMP9 (C), Calpain-2 (E)
or TNFα (G) as compared to corresponding vehicle-treated mice are shown. Response frequency to the von Frey filament at 0.16 g force is
represented on the Y-axis. Changes in GM-CSF-mediated thermal hypersensitivity upon inhibition Rac1 (B), MMP9 (D), Calpain-2 (F) or TNFα (H)
as compared to corresponding vehicle-treated mice are shown. Withdrawal latency in seconds to calibrated radiant heat is represented on the
Y-axis. * denotes P≤ 0.05 as compared to basal values, † denotes P≤ 0.05 relative to corresponding vehicle treated group, One-Way ANOVA with
repeated measures followed Fisher’s LSD Post-hoc analysis , n = 6 mice per group.
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Peripheral calpain2 and TNFα are dispensable in the
mediation of GMCSF-mediated hyperalgesia
In the current study, Capn2, which encodes the calcium-
dependent cysteine proteases calpain 2, emerged as a gene
showing a high level of induction, common to both
GMCSF and GCSF, in sensory neurons. Drugs which
inhibit both Calpain 1 and Calpain 2 have been shown to
inhibit mechanical hyperalgesia following inflammation or
in response to some mediators [37,38]. Therefore, we also
tested the potential of a peripherally administered Calpain
1/2 inhibitor (Calpain inhibitor III, 10 nmol in 10 μl of
10% DMSO) to modulate GMCSF-mediated mechanical
and thermal hyperalgesia using the paradigm described
above and inhibitor concentrations that have been shown
to be effective in previous studies on inflammatory pain
[37,38]. Our analysis showed, however, that GMCSF-
induced hypersensitivity was not significantly different
between mice receiving Calpain1/2 inhibitor or vehicle
(10 μl of 10% DMSO) in all tests and at all time points
tested (Figure 6E and F; Additional file 6: Table S2 and
Additional file 7: Table S3; * P < 0.05 as compared to basal
values; One-way ANOVA with repeated measures follo-
wed by Fisher’s LSD Post-hoc analysis).
In the current study, tumor necrosis factor alpha (TNFα)
was upregulated by 10-fold following GMCSF stimulation
but only moderately following GCSF stimulation in micro-
array or QRTPCR experiments. TNFα inhibition in the
spinal cord has been reported to be protective against
neuropathic pain [39-41] and systemically-applied TNFα
inhibitor protects mice from tumor-induced thermal
hyperalgesia [42]. Moreover, a specific TNFα inhibitor,
namely Etanercept (trade name Enbrel®), has been sug-
gested to be efficacious against autoimmune diseases such
as Crohn’s disease [43] and is in clinical practice for the
treatment of several peripheral inflammatory diseases such
as rheumatoid arthritis [44]. Therefore, we sought out to
investigate the potential of peripherally applied TNFα decoy
receptor, Etanercept, choosing a dose of 100 pmol, which is
slightly higher than the dose reported to reduce neuro-
pathic hypersensitivity [40]. We observed that GMCSF-
induced mechanical and thermal hyperalgesia were not
significantly different between groups treated with vehicle
(BSA) or Etanercept (Figure 6G and H, Additional file 6:
Table S2 and Additional file 7: Table S3; * P < 0.05 following
GM-CSF administration as compared to basal values, One-
way ANOVA with repeated measures followed by Fisher’s
LSD Post-hoc analysis). Thus, albeit TNFα is upregulated
in peripheral sensory neurons following GM-CSF admin-
istration, it does not appear to directly contribute to GM-
CSF-induced nociceptive hypersensitivity.
Discussion
We and others have previously demonstrated that the
hematopoietic growth factors, GMCSF and GCSF, sensitize
sensory nerves directly via activation of receptors located
on sensory nerves and contribute significantly to cancer-
associated pain [8]. Several recent studies have extended
these results to acute and chronic pain in the context of
post-operative pain, inflammatory pain and osteoarthritic
pain [9-12]. Thus, understanding the genomic program
induced in sensory neurons by this set of key cytokines is
crucial for gaining insights into the pathophysiological role
of G-/GMCSF, as well as in developing therapeutic options.
To understand the molecular mediators via which the
GMCSF receptor is exerting its protective pronociceptive
affects, we performed a genome-wide expression screen in
cultured sensory neurons following G-/GMCSF ligand
treatments. Using in-depth systems level in silico analysis,
and in vivo pharmacology to functionally test selected
candidate genes, we present G-/GMCSF-mediated tran-
scriptome change and its importance in modulating
GMCSF-mediated hyperalgesia in the sensory neurons.
One of the most interesting observations of the
present study was that many chemokines such as Ccl3,
Ccl5, insulin-like growth factor 1 (Igf1), Vascular endo-
thelial growth factor A (Vegfa), transcript variant 2 and
TNFα, which are known to play a significant role in pain
modulation [20,26,45,46] are regulated in a G-/GMCSF
dependent manner in sensory neurons. It was previously
reported that the lack of CCL5 results in decreased
hypersensitivity in partial sciatic nerve ligation model of
neuropathic pain. Further, infiltration of pro-inflammatory
cytokines such as tumor necrosis factor-α, [is this supposed
to be alpha?] interleukin [IL]-1b, IL-6, and interferon-c was
significantly reduced in the damaged nerves while that of
anti-inflammatory cytokines such as IL-4 and IL-10 was
significantly increased in the injured nerves following the
global CCL5 loss in mice [26]. TNFα was shown to have a
significant contribution in the development of pain sensi-
tivity following peripheral nerve injury.
Rac1 is a small GTPase ubiquitously expressed in
neurons and other cell types. Spinal cord neurons, astro-
cytes and oligodendrocytes express high levels of Rac1
mRNA and its expression is elevated following spinal cord
injury (SCI) in rats [47]. Intrathecally applied specific Rac1
inhibitor ameliorates SCI-induced changes in spine
morphology, attenuates injury-induced hyper excitability
of wide-dynamic range neurons, and increases SCI-
mediated pain thresholds [31]. Rac1 activity regulates den-
dritic spine morphology in hippocampal neurons through
actin cytoskeleton reorganization and promotes clustering
of glutamate AMPA receptors in spines [48-50]. In the
current study, Rac1 expression increased by about 4–5
fold in sensory neurons following exposure to GMCSF or
GCSF stimulation, suggesting that this may work as a
shared mechanism between GMCSF and GCSF stimuli to
modulate functional as well as structural changes in
sensory neurons. Indeed, we have previously shown that
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knocking down GMCSF receptor-alpha in sensory neu-
rons of the DRG attenuates tumor-induced structural re-
modeling and sprouting of peripheral sensory terminals
[8]. Further, inhibiting Rac1 activity in the peripheral ter-
minals resulted in complete protection from GMCSF-
induced mechanical hypersensitivity and partial protection
from thermal hypersensitivity. These effects of peripher-
ally applied Rac1 inhibitor were devoid of a systemic com-
ponent and did not come about via an alteration of basal
mechanical and thermal sensitivity. These results under-
line the importance of Rac1 in the periphery in the modu-
lation of nociceptive stimuli, in the context of both
mechanical and thermal modalities.
MMP9 is under the transcriptional control of Ets1 and
belongs to a family of extracellular proteases called
matrix metalloproteinases (MMPs) [51]. MMPs play a
critical role in neuroinflammation through the cleavage
of the extracellular matrix (ECM) proteins, cytokines,
and chemokines [52-54]. Consistent with previously
reported changes in MMP9 expression in nervous tissue
following damage to peripheral nerves [33,35,52,55,56],
we observed a 5-fold increase in MMP9 expression
following GMCSF stimulus in sensory neurons. Intra-
thecally administered MMP9 inhibitors have been shown
to block mechanical allodynia associated with peripheral
inflammation [36] as well as nerve injury [35]. Func-
tional experiments performed in the current study show
that MMP9 inhibition in the periphery leads to significant
protection from GMCSF-mediated mechanical hypersen-
sitivity in the absence of a systemic influence or without
affecting basal nociception. Interestingly, these findings
thus indicate that MMP9 exerts pronociceptive effects not
only in the central terminals but also at the peripheral
nerve endings. Our findings further suggest that MMP9
may be linked to the role of GMCSF in tumor-associated
pain, since both inflammatory and neuropathic mecha-
nisms contribute to cancer pain. However, peripheral
blockade of MMP9 did not affect GMCSF-mediated ther-
mal hyperalgesia, which is consistent with a lack of its role
in inflammatory thermal hyperalgesia.
Calpains are a family of ubiquitously expressed
calcium-dependent cysteine proteases and have been
implicated in several cellular processes such as prolifera-
tion, apoptosis and differentiation [57-59], pathological
conditions including neuronal plasticity [60], neuronal
cell death [61]. Proteolytic targets of calpain include
cytoskeletal proteins such as neurofilament, spectrin,
and membrane proteins such as growth factor receptors
[62,63], cytokines [64,65] and transcription factors [66].
In the current study, long-term GMCSF or GCSF ex-
posure led to robust transcriptional increase in the ex-
pression of calpain 2 and 7, but not other calpain family
members, in sensory neurons. However, inhibiting the
calpain 2 protease by using a specific calpain I/II inhibitor
in the periphery did not have any impact on modulating
GMCSF-induced mechanical and thermal hyperalgesia.
This lack of phenotypic changes is not due to a lack of
efficacy of the inhibitor since intrathecal application of
comparable concentrations has been shown to signifi-
cantly reduce zymosan-mediated thermal hypersensitivity
in rats [37] or lysophosphatidic acid (LPA)-mediated ther-
mal hyperalgesia in mice [38]. Thus, our results indicate
that calpain is dispensable for GMCSF-induced nocicep-
tive sensitization in the periphery; however, they do not
rule out that GMCSF-mediated induction of calpain ex-
pression may be modulating other functions and processes
in the DRG which were not studied here.
TNFα is a proinflammatory chemokine which was previ-
ously studied intensively in the context of nociceptive
modulation [67,68]. Importantly, intraperitoneal applica-
tion of TNFα decoy receptor etanercept relieved mice from
tumor-mediated hyperalgesia [42]. However, it was also
reported that intrathecally and intraperitoneally applied
etanercept protects the mice from diabetic neuropathy-
induced mechanical hyperalgesia but intraplantar applica-
tion of the same inhibitor showed inefficient in protecting
the mice from diabetic neuropathy-induced hypersensitiv-
ity [40]. Consistent with this observation, we observed that
peripheral inhibition of TNFα is not sufficient to abrogate
the nociceptive stimulus-mediated sensitivity. Taken to-
gether, these observations suggest that TNFα is recruited
downstream of other tumor-associated mediators.
Other than the genes directly regulated by G-/GMCSF
transcriptionally, our systems level network analysis re-
vealed several other pathways which could be directly
connected to the G-/GMCSF-mediated genes, such as IKK-
NF-κB pathway. This classical, canonical pathway involves
TNFα or IL-1β stimuli via respective receptors leading to
the activation of an inhibitor of the NF-κB (I-κB) kin-
ase complex, consisting of the regulatory subunit I-κB
kinases (IKKs). This pathway is crucial for the activa-
tion of innate immunity and inflammation [69]. Function-
ally, increased NF-κB levels in DRG neurons following
sciatic nerve crush [70] or upregulation of NF- κB transac-
tivation following sciatic nerve transection [71] have been
reported. Pharmacological intervention at several nodes of
the NF-κB pathway has been shown to modulate nocicep-
tive responses [69]. Inactivation of NF-κB specifically in
primary sensory neurons of DRG via Cre-LoxP-mediated
deletion of IKKB inhibitor kappa B kinase beta (IKKβ) has
been shown to have a protective effect on nerve injury-
mediated hyperalgesia [72]. Interestingly, the expression of
TNFα and IL-1β robustly increased following G-/GMCSF
stimuli in the current study, implying a clearer activation
of NF-κB pathway in sensory neurons. Another molecular
pathway which emerged to be very closely connected to
G-/GMCSF-mediated transcriptome in sensory neurons is
caspase signaling. Caspases are a family of proteases and
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play an important role in mediating programmed cell
death following different noxious stimuli [73,74]. Periph-
eral nerve injury promotes neuronal cell death in the
spinal dorsal horn [75-77] and arresting this nerve injury-
induced neuronal loss in the spinal dorsal horn by
blocking caspase activity reduces neuropathy-induced pain
sensitivity [78]. Caspase signaling pathways differentially
contribute to neuropathy-induced and TNF-mediated
pain behaviors [79]. Our results on network analysis indi-
cate that GMCSF signaling may be interlinked with TNF-
alpha and caspase signaling in DRG neurons.
Thus, the striking changes we report in the transcription
of many pain-related ion channels, chemokines, growth
factors and proteases among several other classes of genes
in DRG neurons following prolonged exposure to G-/
GMCSF imply that G-/GMCSF signaling is a trigger point
for activation of multiple pain modulatory pathways and
that blocking the G-/GMCSF signaling may be very effect-
ive in alleviating a broad set of pain disorders.
Conclusion
In summary, the current study demonstrates genome-
wide transcriptome changes following chronic G-/GMCSF
stimulus in the sensory neurons. Utilizing state-of-the art
in silico systems level analysis, this study not only reveals
that several key pain-related genes to be transcriptional
targets of G-/GMCSF signaling, but also provides novel
insights into network interactions with several other novel
candidate genes. Using in vivo pharmacology, we provide
the importance of peripheral MMP9 and Rac1 signaling in
inhibiting GMCSF-mediated mechanical and thermal
hypersensitivity. Thus, with integrative approach of gen-
omics, bioinformatics, in vivo pharmacology and behav-
ioral analyses, this study advances the understanding of
nociceptive mechanisms in sensory neurons and provides
a basis for further pursuing G-/GMCSF signaling in thera-
peutic treatment of pain disorders.
Additional files
Additional file 1: Table S1. Significantly regulated genes following
GMCSF or GCSF chronic stimulus in the sensory neurons with the 2 fold
cut-off and pBH < 0.05 (two-tailed t-test assuming equal variance, P with
Benjamini and Hochberg False Discovery Rate correction <0.05).
Additional file 2: Figure S1. Symbols used to represent different
functional classes of protein to represent direct-interactions networks in
Figures 3 and 4 and network interactions in Additional file 3: Figure S2
and Additional file 4: Figure S3.
Additional file 3: Figure S2. Direct-interactions-network analysis on the
gene pool commonly up- and down-regulated following GMCSF or GCSF
exposure in the sensory neurons. Gene pool with fold-change between +4
and −4 as compared to control-treated sensory neurons and P-BH < 0.05
(t-test, P with Benjamini and Hochberg False Discovery Rate < 0.05). Genes
upregulated and downregulated in GMCSF-dependent manner are marked
with red and blue circles respectively. Please see Additional file 2: Figure S1
for information on legends.
Additional file 4: Figure S3. Gene-ontology enrichment analysis on
gene pools induced by GMCSF (A) and GCSF (B). Analysis was performed
using bioCompendium online repository (http://biocompendium.embl.
de) using the gene pool with fold-change between +2 and −2, as
compared to control-treated sensory neurons and P-BH < 0.05 (t-test, P
with Benjamini and Hochberg False Discovery Rate <0.05). Percent of G-/
GM-CSF induced genes over total input number of genes significantly
enriched are represented in both panels (P-BH < 0.05, as compared to
mouse genome, hypergeometric statistical method).
Additional file 5: Figure S4. Top scored network obtained from the
gene pool regulated by GM-CSF stimulus in sensory neurons, using the
same set of genes explained in the Figure 1-A. Genes upregulated and
downregulated in GMCSF-dependent manner are shown with red and
blue circles respectively. Thick cyan lines indicate the fragments of
canonical pathways. Please refer Additional file 2: Figure S1 for the
symbols representing different generic classes of proteins.
Additional file 6: Table S2. Impact of inhibition of Rac1, MMP9, Calpain2
or TNFα on GMCSF-mediated mechanical hypersensitivity. Response
frequencies to calibrated von Frey filaments of different strength at paws
ipsilateral and contralateral to intraplantar GMCSF administration are shown
as compared to corresponding vehicle-treated mice. * denotes P≤ 0.05 as
compared to basal values, † denotes P≤ 0.05 relative to corresponding
vehicle-treated group, One-Way ANOVA with repeated measures followed
Fisher’s LSD Post-hoc analysis , n = 6 mice per group.
Additional file 7: Table S3. Impact of Inhibition of Rac1, MMP9,
Calpain2 or TNFα on GMCSF-mediated thermal hypersensitivity.
Withdrawal latency in seconds to calibrated radiant heat from the paws
ipsilateral and contralateral to intraplantar GMCSF administration are
shown as compared to corresponding vehicle-treated mice. * denotes
P≤ 0.05 as compared to basal values, † denotes P≤ 0.05 relative to
corresponding vehicle treated group, One-Way ANOVA with repeated
measures followed Fisher’s LSD Post-hoc analysis, n = 6 mice per group.
Additional file 8: Figure S5. Systemic effects of intraplantar application
of inhibitors of specific pathways on GMCSF-induced nociceptive
sensitization. Changes in the GMCSF-mediated mechanical
hypersensitivity in the paw ipsilateral to the GMCSF-injected paw
following Rac1 (A) or MMP9 (B) inhibitors application in the paw
contralaeral to GMCSF-injected paw or changes in the GM-CSF-mediated
mechanical hypersensitivity in the paw contralateral to the GMCSF-injected
paw following Rac1 (E) or MMP9 (F) inhibitors application in the paw
contralaeral to GMCSF-injected paw as compared to corresponding vehicle-
treated mice are shown. Response frequency to the von Frey filament at
0.16 g force is represented on the Y-axis. Changes in the GMCSF-mediated
thermal hypersensitivity in the paw ipsilateral to the GMCSF-injected paw
following Rac1 (C) or MMP9 (D) inhibitors or changes in the GMCSF-
mediated thermal hypersensitivity in the paw contralateral to the GMCSF-
injected paw following Rac1 (G) or MMP9 (H) inhibitors as compared to
corresponding vehicle-treated group of mice. Withdrawal latency in
seconds to calibrated radiant heat is represented. * denotes P≤ 0.05 as
compared to basal values, One-Way ANOVA with repeated measures
followed Fisher’s LSD Post-hoc analysis, n = 6 mice per group.
Additional file 9: Figure S6. Effect of blockade of Rac1 or MMP9 on basal
mechanical and thermal sensitivity. Changes in the perception of mechanical
sensitivity in response to von Frey filaments of increasing strength in the paw
ipsilateral to the Rac1 (A) or MMP9 (C) inhibitor application is compared to
the response frequency before inhibitor application (basal). Percentage
Response frequency to the von Frey filament at 0.16 g force is represented
on the Y-axis. Changes in the response to thermal stimuli following Rac1 (B)
or MMP9 (D) inhibitors as compared to basal reading. Withdrawal latency in
seconds to calibrated radiant heat is represented. * denotes P≤ 0.05 as
compared to basal values, One-Way ANOVA with repeated measures
followed Fisher’s LSD Post-hoc analysis , n = 6 mice per group.
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